This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy X4 Pharmaceuticals stock | $6.92

Own X4 Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

X4 Pharmaceuticals, Inc is a biotechnology business based in the US. X4 Pharmaceuticals shares (XFOR) are listed on the NASDAQ and all prices are listed in US Dollars. X4 Pharmaceuticals employs 68 staff and has a trailing 12-month revenue of around USD$3 million.

How to buy shares in X4 Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for X4 Pharmaceuticals. Find the stock by name or ticker symbol: XFOR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until X4 Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$6.92, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of X4 Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of X4 Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

X4 Pharmaceuticals share price

Use our graph to track the performance of XFOR stocks over time.

X4 Pharmaceuticals shares at a glance

Information last updated 2020-12-03.
Latest market close USD$6.92
52-week range USD$5.38 - USD$12.96
50-day moving average USD$6.4211
200-day moving average USD$7.7728
Wall St. target price USD$18.43
PE ratio 5.4865
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.721

Buy X4 Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy X4 Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

X4 Pharmaceuticals price performance over time

Historical closes compared with the close of $6.92 from 2020-12-04

1 week (2020-11-25) 7.79%
1 month (2020-11-04) 7.45%
3 months (2020-09-04) -16.22%
6 months (2020-06-04) -19.44%
1 year (2019-12-04) -32.02%
2 years (2018-12-04) 105.34%
3 years (2017-12-04) -57.55%
5 years (2015-12-02) N/A

Is X4 Pharmaceuticals under- or over-valued?

Valuing X4 Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of X4 Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

X4 Pharmaceuticals's P/E ratio

X4 Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, X4 Pharmaceuticals shares trade at around 5x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

X4 Pharmaceuticals financials

Revenue TTM USD$3 million
Gross profit TTM USD$0
Return on assets TTM -26.89%
Return on equity TTM -64.65%
Profit margin 0%
Book value $5.508
Market capitalisation USD$109.9 million

TTM: trailing 12 months

Shorting X4 Pharmaceuticals shares

There are currently 328,171 X4 Pharmaceuticals shares held short by investors – that's known as X4 Pharmaceuticals's "short interest". This figure is 4.9% up from 312,732 last month.

There are a few different ways that this level of interest in shorting X4 Pharmaceuticals shares can be evaluated.

X4 Pharmaceuticals's "short interest ratio" (SIR)

X4 Pharmaceuticals's "short interest ratio" (SIR) is the quantity of X4 Pharmaceuticals shares currently shorted divided by the average quantity of X4 Pharmaceuticals shares traded daily (recently around 72125.494505495). X4 Pharmaceuticals's SIR currently stands at 4.55. In other words for every 100,000 X4 Pharmaceuticals shares traded daily on the market, roughly 4550 shares are currently held short.

However X4 Pharmaceuticals's short interest can also be evaluated against the total number of X4 Pharmaceuticals shares, or, against the total number of tradable X4 Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case X4 Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 X4 Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0204% of the tradable shares (for every 100,000 tradable X4 Pharmaceuticals shares, roughly 20 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against X4 Pharmaceuticals.

Find out more about how you can short X4 Pharmaceuticals stock.

X4 Pharmaceuticals share dividends

We're not expecting X4 Pharmaceuticals to pay a dividend over the next 12 months.

Have X4 Pharmaceuticals's shares ever split?

X4 Pharmaceuticals's shares were split on a 1:6 basis on 14 March 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your X4 Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for X4 Pharmaceuticals shares which in turn could have impacted X4 Pharmaceuticals's share price.

X4 Pharmaceuticals overview

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site